The safety of angiotensin II receptor blockers (ARBs) for the treatment of hypertension and cardiovascular and renal diseases has been well documented in numerous randomized clinical trials involving thousands of patients. However, recent concerns have surfaced about possible links between ARBs and increased risks of myocardial infarction and cancer. Less is known about the safety of the direct renin inhibitor aliskiren, which was approved as an antihypertensive in 2007. This article provides a detailed review of the safety of ARBs and aliskiren, with an emphasis on the risks of cancer and myocardial infarction associated with ARBs. Safety data were identified by searching PubMed and Food and Drug Administration (FDA) Web sites through April 2011. ARBs are generally well tolerated, with no known class-specific adverse events. The possibility of an increased risk of myocardial infarction associated with ARBs was suggested predominantly because the Valsartan Antihypertensive Long-Term Use Evaluation (VALUE) trial reported a statistically significant increase in the incidence of myocardial infarction with valsartan compared with amlodipine. However, no large-scale, randomized clinical trials published after the VALUE study have shown a statistically significant increase in the incidence of myocardial infarction associated with ARBs compared with placebo or non-ARBs. Meta-analyses examining the risk of cancer associated with ARBs have produced conflicting results, most likely due to the inherent limitations of analyzing heterogeneous data and a lack of published cancer data. An ongoing safety investigation by the FDA has not concluded that ARBs increase the risk of cancer. Pooled safety results from clinical trials indicate that aliskiren is well tolerated, with a safety profile similar to that of placebo. ARBs and aliskiren are well tolerated in patients with hypertension and certain cardiovascular and renal conditions; their benefits outweigh possible safety concerns.
Introduction
The renin-angiotensin system (RAS) consists of a group of hormones, which regulates blood pressure (BP), fluid and electrolyte balance, tissue perfusion, and vascular growth. 1, 2 The RAS plays an important role in the pathophysiology of cardiovascular and renal disease, 3 and antihypertensive therapies that target the RAS are used in the management of hypertension, congestive heart failure, myocardial infarction, stroke, high cardiovascular risk, diabetes, and renal failure. 2, 3 In addition, antihypertensive drugs that block the RAS may provide organ protection by acting on local RAS functions in tissues, such as the kidneys, heart, eyes, and brain.
Over the last two decades, several angiotensin II receptor blockers (ARBs; eg, losartan, valsartan, telmisartan, olmesartan) have been approved as antihypertensive therapies. 11 ARBs provide clinically meaningful benefits for patients with cardiovascular and/or renal disease, 11 and ARBs generally have better tolerability profiles than ACE inhibitors. 12 Cough is not an AE associated with ARB therapy; however, when ARBs are used in combination with ACE inhibitors, there is an increased risk of renal dysfunction and hyperkalemia. 4 Over the past several years, concerns have surfaced about possible links between ARBs and increased risks of cancer 13 and myocardial infarction. 14 Direct renin inhibitors (DRIs) are a new class of antihypertensive agents that target the initial rate-limiting step of the RAS. 15 Several DRIs have been developed as antihypertensive therapies; however, early DRIs, including enalakiren, remikiren, and zankiren, had poor bioavailability, weak antihypertensive effects, and short durations of action. 4, 15 Aliskiren is the only DRI that is approved by the United States Food and Drug Administration (FDA) for the treatment of hypertension, 16 but several other DRIs are in the early stages of clinical development. 17, 18 In clinical studies, the AE profile of aliskiren was similar to that of placebo, with a lower incidence of cough than ACE inhibitors. 15, 16 The main purpose of this article is to review the safety of ARBs and the DRI aliskiren, including a detailed examination of the risks of cancer and myocardial infarction associated with ARBs. A brief overview of the RAS and efficacy of ARBs and aliskiren is also provided.
Overview of the RAS
Key steps in the RAS are shown in Figure 1 . 3 Following conversion from its precursor prorenin, the aspartate protease renin is secreted by granular cells of the juxtaglomerular apparatus in the kidney. 3, 19 The biosynthesis and release of renin are key elements in determining the capacity of the RAS to regulate BP and respond to fluid changes. 3 Renin catalyzes the conversion of angiotensinogen to angiotensin I, which is the rate-limiting step in the RAS. 15 DRIs block this step and reduce plasma renin activity. 15 ACE catalyzes the conversion of angiotensin I to angiotensin II, and ACE inhibitors block this step in the RAS. 15 Angiotensin II binds to angiotensin II type-1 (AT 1 ) receptors, which regulates BP via several mechanisms and provides feedback inhibition of further release of renin by the kidneys. 15 ARBs block the AT 1 receptor, reducing the effects of angiotensin II. 4 ARBs and ACE inhibitors may not provide comprehensive suppression of the RAS because they disrupt the negative feedback effect of angiotensin II on renin release, resulting in an increase in plasma renin concentration and plasma renin activity.
2,4 ACE inhibitors also increase angiotensin I concentrations, and although ACE inhibitors prevent the conversion of angiotensin I to angiotensin II, angiotensin II production can still occur through non-ACE-dependent pathways involving enzymes such as chymase and chymotrypsin-like angiotensin-generating enzyme. 1, 15 In addition, ACE inhibitors block the degradation of bradykinin, and the resulting increase in bradykinin concentration may be a factor in the development of cough and angioedema associated with these agents. 15 DRIs may provide more optimal suppression of the RAS by interrupting the system at its first regulated step, resulting in decreased plasma renin activity.
1,2,15

Efficacy of ARBs and the DRI aliskiren
In 1995, losartan was the first ARB to receive FDA approval as an antihypertensive. Since then, six other ARBs and the DRI aliskiren have also been approved for the treatment of hypertension; several of these agents also have other cardiovascular indications. 20 Approved indications, dosing information, and dates of FDA approval for the ARBs and aliskiren are shown in Table 1 .
ARBs
Data from numerous randomized clinical trials indicate that ARB therapy is effective in reducing complications related to hypertension 5 and in slowing or blocking the progression of cardiovascular disease. 11 As a class of drugs, ARBs have
Dovepress
299
Safety of angiotensin receptor blockers and direct renin inhibition
shown clinical benefits for patients with heart failure, diabetes, and chronic kidney disease. 5 Pharmacologic and dosing differences exist among the seven ARBs approved as antihypertensive agents; 11, 20 therefore, efficacy and safety results for one ARB cannot be extrapolated to other ARBs. 20 In general, newer ARBs are more effective than losartan in lowering BP in patients with hypertension based on the results of head-tohead comparative studies. 11 Recent reviews 11, 20 have compared the efficacy of ARBs vs non-ARBs in different clinical settings. These results are summarized in Table 2 .
The DRi aliskiren
The effects of aliskiren on cardiovascular and renal morbidity and mortality are currently unknown. However, several outcomes studies are underway as part of the ASPIRE HIGHER clinical trials program, which will help to better define the role of direct renin inhibition in clinical practice. 1 When administered alone or in combination with other agents, including thiazide diuretics, calcium-channel blockers, or RAS-blocking drugs (ie, ACE inhibitors or ARBs), treatment with aliskiren effectively lowers BP in a variety of hypertensive populations (eg, diabetic, obese, elderly). 1, 21 In several randomized, double-blind clinical trials, treatment with aliskiren has been associated with positive effects on surrogate markers of cardiovascular and renal disease, including urinary albumin, N-terminal pro-brain natriuretic peptide (NT-proBNP), and left ventricular mass index. [22] [23] [24] For example, in the Aliskiren in the Evaluation of Proteinuria in Diabetes (AVOID) trial in patients with hypertension and type 2 diabetes with nephropathy, 22 aliskiren 300 mg/day combined with losartan 100 mg/day reduced the mean urinary albuminto-creatinine ratio by 20% (95% confidence interval [CI]: 9% to 30%; P , 0.001) compared with losartan 100 mg/day plus placebo. In the Aliskiren Observation of Heart Failure Treatment (ALOFT) trial 23 involving patients with New York Heart Association (NYHA) class II to IV heart failure and a history of hypertension, addition of aliskiren to an ACE inhibitor (or ARB) and β-blocker significantly reduced NT-proBNP concentrations compared with placebo. In the Aliskiren in Left Ventricular Hypertrophy (ALLAY) trial, 24 which included overweight patients with hypertension and increased ventricular wall thickness, treatment with aliskiren or losartan resulted in similar reductions in left ventricular mass index.
In a recent study ( 
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-(e-COST) Notes: + designates that the study achieved its primary or secondary endpoint(s); -designates that study did not meet its primary or secondary endpoint(s); This table is a summary of fully published randomized controlled trial data (ie, no data from single-arm noncomparative trials were considered), with an emphasis on large-scale trials (when available). Additional smaller studies were considered in the absence of data from large-scale clinical trials; *Stroke data were not specific to primary or secondary prevention in the main analysis;
† Stroke was evaluated in a post-hoc analysis, not as a prespecified endpoint. myocardial infarction gave no further protection against ventricular remodeling. 25 However, the researchers conducted a post-hoc subgroup analysis and found that patients with diabetes (n = 148) were the only subgroup that had a borderline interaction in treatment effect. There were more AEs in patients assigned to aliskiren, but the total number of serious AEs was similar in the two arms. Specifically, AEs that occurred at a higher incidence in aliskiren recipients compared with placebo recipients included hyperkalemia (5.2% vs 1.3%), hypotension (8.8% vs 4.5%), and renal dysfunction (2.4% vs 0.8%). Elevations in blood urea nitrogen and creatinine were more likely in the aliskiren group, and patients assigned to aliskiren were more likely to have a potassium value measured at .5.5 mmol/L or at $6 mmol/L. Although these results do not provide support for testing the use of aliskiren in a morbidity and mortality trial in this population of high-risk postmyocardial infarction patients, ASPIRE used a surrogate endpoint and was not powered to assess hard clinical outcomes. Aliskiren is currently being studied in ongoing outcomes trials of patients with chronic heart failure and diabetic nephropathy to assess the role of direct renin inhibition in these populations.
Safety of ARBs and the DRI aliskiren Safety of ARBs
As a class of agents, ARBs are well tolerated, with safety profiles similar to that of placebo. No class-specific AEs have been associated with ARBs. 26 ARBs are contraindicated for women who are pregnant or may become pregnant because of the risk of fetal developmental abnormalities, and ARBs are not recommended for women who are breastfeeding. 5 Several antihypertensive drugs have been associated with an increased risk of erectile dysfunction (ED); however, ARBs have not been observed to increase the risk of ED. 5 In patients whose renal function may depend on the activity of the RAS (eg, patients with severe congestive heart failure), treatment with ARBs may be associated with oliguria and/or progressive azotemia; rarely, acute renal failure and/or death have been reported in these patients. ARBs may also increase serum creatinine and/or blood urea nitrogen levels in patients with unilateral or bilateral renal-artery stenosis.
27,28
ARBs and myocardial infarction
In 2004, an editorial by Verma and Strauss 14 raised concerns that ARBs may increase the risk of myocardial infarction based on results of the Valsartan Antihypertensive LongTerm Use Evaluation (VALUE) trial, 29 which reported a statistically significant 19% relative increase in myocardial infarction with valsartan compared with the calcium-channel blocker amlodipine. Responses to this article from the medical community were mixed. Several follow-up editorials and analyses [30] [31] [32] [33] cited the need to evaluate the risk of myocardial infarction associated with ARBs more systematically and in a broader clinical context. However, other publications noted that there are possible mechanisms by which ARBs could predispose patients to myocardial infarction. 12, 34 In 2006, Strauss and Hall 12 used the term "ARB-MI Paradox" to describe the unexpected observation that in some clinical trials involving patients at high cardiovascular risk, the BP-lowering effects of ARBs did not reduce the risk of myocardial infarction compared with placebo, and in some cases treatment with ARBs may have increased the risk of myocardial infarction. The authors went on to provide a plausible biological mechanism by which ARBs could increase the incidence of myocardial infarction by increasing circulating levels of angiotensin II. Increased angiotensin II levels cause up-regulation of angiotensin type-2 (AT 2 ) receptors. While AT 2 -receptor stimulation may provide beneficial effects by mediating vasodilation and nitric oxide release, AT 2 -receptor stimulation may also mediate growth promotion, fibrosis, and hypertrophy, and may have pro-atherogenic and pro-inflammatory effects. The authors concluded that results from meta-analyses [35] [36] [37] [38] support the "ARB-MI Paradox" because they show that ARBs are associated with an increased risk of coronary heart disease events and/or a lack of BP-related vascular benefits.
Following the publication of the editorial by Verma and Strauss, 14 several meta-analyses were performed analyzing cardiovascular event outcomes across multiple clinical trials involving ARBs. Results of these analyses were mixed, with some studies reporting no increased risk of myocardial infarction associated with ARBs, 33, 35, 36 while other studies 12,39 report a trend toward increased risk of myocardial infarction with ARBs. While meta-analyses can be powerful tools to summarize data across multiple studies, they also have significant limitations. 40 Identification and selection of studies can be biased and availability of results may limit the analyses that can be performed. The choice of statistical analysis methods (ie, fixed-effects vs random-effects models) can also affect the outcome of the meta-analysis. In addition, heterogeneity of data between different studies (eg, disease states, follow-up time, treatment regimens) may make it difficult to create a meaningful integration of results. 40 Limitations specifically acknowledged in the meta-analyses that evaluated the risk of myocardial infarction associated with ARBs included heterogeneity of data across studies, limited availability of data on the incidence of myocardial infarction, varying definitions of myocardial infarction between studies, and the potential for confounding effects of different treatments on the incidence of myocardial infarction.
35,36 Table 3 shows the incidence of myocardial infarction reported in randomized clinical trials of ARBs that had a mean or median follow-up time of at least 1 year and enrolled at least 1000 patients with a range of cardiovascular and renal conditions. Since the publication of the Verma and Strauss editorial, 14 considerably more data have become available on the incidence of myocardial infarction Percentages reported in the e-COST study are based on the intent-to-treat population (n = 815 for both treatment groups); b Number (%) of patients who had $1 Mi; Because patients could have more than 1 Mi, the number of investigator-reported Mis was 798 in the captopril group, 796 in the valsartan group, and 756 in the captopril + valsartan group. In the Ongoing Telmisartan Alone and in Combination With Ramipril Global Endpoint Trial (ONTARGET) study, 42 which enrolled patients with vascular disease or high-risk diabetes, the RR for fatal or nonfatal myocardial infarction was 1.07 (95% CI: 0.94-1.22) for telmisartan compared with the ACE inhibitor ramipril. The RR for myocardial infarction for combination therapy with telmisartan and ramipril vs ramipril alone was 1.08 (95% CI: 0.94-1.23). 42 In the Telmisartan Randomized Assessment Study in ACE Intolerant Subjects With Cardiovascular Disease (TRANSCEND) study, 43 which also included patients with diabetes with end-organ damage, the incidence of myocardial infarction was 3.9% (116/2954) in patients treated with telmisartan and 5.0% (147/2972) in patients who received placebo (hazard ratio [HR] for telmisartan vs placebo, 0.79; 95% CI: 0.62-1.01; P = 0.059). 43 Results of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) study 44 showed that the event rate for fatal or nonfatal myocardial infarction was not significantly different for valsartan compared with placebo in patients with impaired glucose tolerance and cardiovascular disease or cardiovascular risk factors (HR: 0.97; 95% CI: 0.77-1.23; 1-sided P = 0.41; 2-sided P = 0.83). In the KYOTO HEART study, 45 in Japanese patients with uncontrolled hypertension, the HR for acute myocardial infarction for valsartan compared with non-ARB antihypertensive treatment was 0.65 (95% CI: 0.2-1.8; P = 0.39). Results from the Jikei Heart Study 46 in Japanese patients with hypertension, coronary heart disease, and/or heart failure showed a HR for new or recurrent acute myocardial infarction of 0.90 (95% CI: 0.47-1.74; P = 0.75) for valsartan compared with non-ARB therapy.
The Irbesartan in Heart Failure With Preserved Systolic Function (I-PRESERVE) 47 and Prevention Regimen for Effectively Avoiding Second Strokes (PROFESS) 48 studies did not report statistical analyses for the difference in the incidence of myocardial infarction between ARBs (irbesartan and telmisartan, respectively) and placebo; however, the incidences of myocardial infarction were numerically similar between the ARBs and placebo (Table 3) , and no significant differences were observed in the HR for death from cardiovascular causes. In the I-PRESERVE study, 47 the HR for death from a cardiovascular cause or nonfatal myocardial infarction or stroke was 0.99 (95% CI: 0.86-1.13; P = 0.84) for irbesartan vs placebo, and in the PROFESS study, 48 the HR for death from cardiovascular causes, recurrent stroke, myocardial infarction, or new or worsening heart failure was 0.94 (95% CI: 0.87-1.01; P = 0.11) for telmisartan vs placebo.
Two other landmark randomized clinical trials involving ARBs are not listed in Table 3 because the published results of these studies did not report the incidence of myocardial infarction. The Valsartan Heart Failure Trial (Val-HeFT) study 49 evaluated the effects of valsartan as add-on therapy to standard treatment for heart failure in patients with NYHA class II, III, or IV heart failure. In this study, treatment with valsartan reduced the incidence of mortality and morbidity (defined as cardiac arrest with resuscitation, hospitalization for heart failure, or receipt of intravenous inotropic or vasodilator therapy for $4 hours) by 13.2% compared with placebo (RR: 0.87; 97.5% CI: 0.77-0.97; P = 0.009). Results of the Morbidity and Mortality After Stroke, Eprosartan Compared With Nitrendipine for Secondary Prevention (MOSES) trial 50 showed that the incidence density ratio for cardiovascular events (including myocardial infarction and new cardiac failure) over a mean follow-up time of 2.5 years was lower for eprosartan compared with the calcium-channel blocker nitrendipine (0.75; 95% CI: 0.55-1.02; P = 0.06) in patients with hypertension and history of stroke.
ARBs and cancer
A possible link between an increased incidence of cancer and the use of antihypertensive drugs, including β-blockers, calcium-channel blockers, diuretics, and the alkaloid reserpine, has been suggested by several studies. 9 However, the majority of these possible associations remain unproven or highly uncertain. 9 Results from animal studies have suggested a possible biological mechanism by which ARBs could increase tumor cell proliferation and angiogenesis through selective blockade of AT 1 receptors. 51 This selective blockade results in increased stimulation of AT 2 receptors by angiotensin II. Studies in mice 52, 53 have shown that AT 2 -receptor blockade and gene deletion is associated with decreased expression of pro-angiogenic vascular endothelial growth factor and increased expression of thrombospondin-1. 
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A recent meta-analysis by Sipahi and colleagues 13 found a modestly increased risk of cancer associated with ARBs. Based on an analysis of 5 randomized controlled trials that had a follow-up of at least 1 year, the risk of developing new cancer was 7.2% (2510/35015) among patients treated with ARBs, compared with 6.0% (1602/26575) for controls (RR: 1.08; 95% CI: 1.01-1.15; P = 0.016). In the trials included in this analysis, telmisartan was the study drug for 85.7% (n = 30014) of patients who received an ARB. Analysis of the trials involving telmisartan showed that the RR for development of new cancer in patients treated with telmisartan compared with controls was 1.07 (95% CI: 1.00-1.14; P = 0.05).
The authors 13 also analyzed the results of 5 trials (N = 68 402) for the occurrence of common types of solid organ cancers (ie, breast, lung, and prostate cancer); these results are summarized in In addition to the limitations of meta-analyses discussed previously, 40 there are several limitations specific to the metaanalysis performed by Sipahi and colleagues 13 that should be considered when interpreting these results. The duration of follow-up in the trials included in this meta-analysis ranged from 1.9-4.8 years. Because cancer is a relatively rare occurrence in any time period of less than 5 years, it has been argued that the duration of follow-up in these trials was too short to draw any meaningful conclusions about the development of new cancers. 54 In addition, development of cancer is a relatively rare AE, and rare AEs are often not analyzed statistically in randomized clinical trials because of small sample sizes; this problem can persist even when data are pooled. 40 It is also important to note that these results are based on post-hoc analyses, and the primary studies were not designed to test for the development of cancer. 13 Further, it is not appropriate to draw conclusions about a possible class effect for all ARBs based on results of this metaanalysis because telmisartan was the study drug in 85.7% of patients who received ARBs. Because the different ARBs have unique pharmacologic and dosing properties, 20 results heavily weighted for telmisartan cannot be extrapolated to the entire class of medications. As noted by Sipahi and colleagues, publication bias was also a significant limiting factor in this meta-analysis. There is a lack of published and/ or publicly available information on the incidence of cancer observed in clinical trials of ARBs. 20 Specifically, many large trials (eg, VALUE, 29 Study on Cognition and Prognosis in the Elderly [SCOPE] 55 ) did not collect cancer data or did not provide their cancer data to the authors of this study; of 60 trials identified as meeting the inclusion criteria for this analysis, data on cancer incidence and/or cancer deaths were only available from nine trials. 13 In addition, the authors of this meta-analysis did not have access to patient-level data to determine whether factors such as age, sex, and smoking status may have influenced the results. 13 Subsequently, a second meta-analysis 56 was performed to assess whether there is an increased risk of cancer associated with antihypertensive therapy. Results of this analysis 56 refuted the results of the Sipahi study. 13 In their meta-analysis, Bangalore and colleagues identified 70 randomized clinical trials of antihypertensive agents (ARBs, ACE inhibitors, calcium-channel blockers, and diuretics) involving 324,168 patients and found no increased risk of cancer associated with ARBs compared with placebo or other antihypertensive controls using random-effects and fixed-effect models (Table 5) . 56 However, in a fixed-effect model, the combination of ARBs with ACE inhibitors was associated with an increased cancer risk compared with placebo and compared with ARBs (Table 5 ). When the results of individual trials of ARBs were evaluated for cancer risk and cancer-related death, ARBs did not differ significantly vs comparators (Figure 2 ). In addition, results did not differ for telmisartan compared with other ARBs.
A third meta-analysis, 57 conducted by the ARB Trialists Collaboration, evaluated the incidence of cancer in 15 long-term, randomized, controlled trials that involved 138,769 patients at high risk for cardiovascular disease who received ARBs (telmisartan, irbesartan, valsartan, candesartan, or losartan). In this analysis, the trials included were required to have an average follow-up time of at least 12 months. Similar to the Bangalore meta-analysis, 56 no increased risk of cancer with ARBs was identified; the cancer incidence in the 15 trials was 6.16% (4549/73,808) in the ARB groups vs 6.31% (3856/61 106) in the control groups (odds ratio [OR]: 1.00; 95% CI: 0.95-1.04; P = 0.886). In addition, no increased cancer risk was observed when evaluating the individual ARBs, and no differences were observed in the incidences of lung, prostate, or breast cancers between ARBs and controls. This analysis also examined cancer risk of ARB/ACE inhibitor combinations submit your manuscript | www.dovepress.com
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vs ACE inhibitors alone, ARBs alone vs ACE inhibitors alone, and ARBs vs placebo/controls without ACE inhibitors. No increased risk of cancer was observed in any of these overall comparisons (Figure 3) . A nominal increase in cancer risk was observed with the ARB/ACE inhibitor combination in one trial (ONTARGET) but a reduced cancer risk was observed with this combination in another (VALIANT). Thus, the authors concluded that the increased risk of cancer observed with the ARB/ACE inhibitor combination may be due to chance and that further study is needed to resolve this question.
Because cancer was not a prespecified outcome in most randomized clinical trials involving ARBs, the amount of published information discussing cancer rates in individual randomized clinical trial results is limited. The authors of both the Sipahi 13 and Bangalore 56 studies searched FDA dockets for information on cancer submitted to the FDA during drug approval processes, labeling changes, and FDA meeting minutes. The authors of the Bangalore study 56 also contacted authors and study investigators via email to obtain additional unpublished cancer data. The authors of the ARB Trialists analysis 57 had access to individual data for several studies with prespecified methods for cancer identification and tabulated cancer outcomes data for the other trials.
The Bangalore 56 and ARB Trialists 57 meta-analyses were more robust than the Sipahi meta-analysis 13 because more trials were included and multiple comparison analysis was performed on the network of different treatments. However, the authors of the Bangalore study 56 acknowledge several limitations including the possibility that the survival benefit associated with antihypertensive therapy compared with placebo may have introduced a "survival bias" that increased the incidence of cancer in active treatment groups. For all the meta-analyses, there may have been other confounding variables that are nearly impossible to measure, such as exposure to radiation or carcinogens. None took into consideration the incidence of a specific cancer in the general population. In addition, the selection criteria used to include trials in these meta-analyses could have influenced the findings (ie, certain trials when put together could increase, decrease, or have no effect on cancer risk). Moreover, results are limited by the short-term nature of most trials and the relatively short duration of exposure to the drugs in question to determine cancer risk. Finally, publication bias, issues with heterogeneity, and availability of data can affect any meta-analysis.
Several population-based studies have evaluated the association between antihypertensive treatment and cancer over the years. A recent analysis by Huang and colleagues specifically investigated the association between ARBs and the occurrence of new cancers in 109,002 patients with newly diagnosed hypertension. 58 Patients were identified from a random sample of 1 million individuals of mostly Chinese ethnicity using the Taiwanese National Health Insurance database. Over an average follow-up period of 5.7 years, a total of 9067 cases of new cancer were reported with a significantly lower occurrence among patients receiving ARBs than not receiving ARBs (3082 vs 5985; P , 0.001). This was the case after adjusting for age, sex, comorbidities, and medications for hypertension control (HR: 0.66; 95% CI: 0.63-0.68; P , 0.001). Consistent results were observed regardless of ARB and for all types of cancer, although conclusions regarding cause and effect cannot be established.
Based on the results of the Sipahi study, the FDA initiated a safety review of ARBs. 59 In July 2010, the FDA issued a communication stating that their results to date indicated that the benefits of ARB therapy outweighed the risks. The FDA did not conclude that ARBs increase the risk of cancer but they will continue their analysis and update the public as more data become available. Notes: *"All aliskiren" includes patients who have received aliskiren as monotherapy or in combination with other antihypertensive agents. Data are number (%) of patients. Data are presented according to the treatment group to which patients were randomized, irrespective of doses used during any titration periods. Abbreviations: ACei, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; HCTZ, hydrochlorothiazide.
Safety of aliskiren
The clinical studies conducted to date with aliskiren have shown this agent to be well tolerated with an AE profile similar to that of placebo, although the treatment duration has been too short to evaluate potential risk for myocardial infarction or cancer. The most commonly reported AEs were fatigue, headache, dizziness, diarrhea, nasopharyngitis, and back pain. 15 Because aliskiren does not inhibit or induce cytochrome P450 isoenzymes, it has relatively few interactions with other drugs. 15 Aliskiren is contraindicated for women who are pregnant or may become pregnant because of the risk of fetal and neonatal morbidity and mortality associated with drugs that act on the RAS. 60 To evaluate the safety and tolerability of aliskiren, White and colleagues pooled safety data from 12 randomized clinical trials of aliskiren involving 12,188 patients with hypertension. 16 The studies included in this analysis were categorized as short term (8 weeks) placebo controlled or long term (26-52 weeks) active controlled. In the short-term studies (n = 8862), AEs were reported by 33.6%, 31.6%, and 36.8% of patients treated with aliskiren 150 mg, aliskiren 300 mg, and placebo, respectively. Serious AEs occurred in 0.4%, 0.5%, and 0.7% of patients treated with aliskiren 150 mg, aliskiren 300 mg, and placebo, respectively. The rate of discontinuation due to AEs was #1.4% for both aliskiren doses and 2.6% for placebo. In the long-term studies (n = 3326), AEs were reported by 33.7% of patients treated with aliskiren 150 mg, 43.2% of patients treated with aliskiren 300 mg, 60.1% of patients treated with ACE inhibitors, 53.9% of patients treated with ARBs, and 48.9% of patients treated with thiazide diuretics. Serious AEs occurred in 3.4% of patients treated with aliskiren (both doses), compared with 2.4%, 8.4%, and 1.7% of patients treated with ACE inhibitors, ARBs, and thiazide diuretics, respectively. The rate of discontinuation due to AEs was 3.2%, 1.7%, 6.9%, 6.5%, and 3.3% for the aliskiren 150-mg, aliskiren 300-mg, ACE inhibitors, ARBs, and thiazide diuretics groups, respectively. Incidences of AEs of special interest (possibly related to RAS agents) are listed in Table 6 . The incidence of cough was low for all aliskiren 
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Safety of angiotensin receptor blockers and direct renin inhibition treatment groups; it was similar to that of placebo in the short-term studies and lower than ACE inhibitors in the long-term studies. In the short-term studies, the incidence of abnormalities in prespecified laboratory values was low and similar to placebo. In the aliskiren 150-mg, aliskiren 300-mg, and placebo groups, respectively, 0.9%, 1.6%, and 1.3% of patients had serum potassium levels .5.5 mEq/L at any visit during the double-blind treatment period. In the long-term studies, 5.7% of patients treated with aliskiren 300 mg had serum potassium levels .5.5 mEq/L, compared with 1.9% to 3.7% of patients in all other treatment groups. Overall, the safety profile of aliskiren was similar to that of placebo and similar or superior to other antihypertensive agents. 16 
Conclusions
ARBs are well tolerated, with a class safety profile similar to that of placebo and no known class-specific AEs. Results from meta-analyses evaluating the risks of myocardial infarction or cancer associated with ARBs have been inconsistent, and caution should be used when evaluating the results of these analyses because even the most well designed and carefully executed meta-analyses have significant limitations. Evidence from landmark, randomized clinical trials published to date does not suggest a link between ARBs and an increased risk of cancer or myocardial infarction. The FDA's position on ARB use is that the benefits of these drugs outweigh their risks, and the FDA has not concluded that ARBs increase the risk of cancer. The DRI aliskiren is also a well-tolerated antihypertensive drug, with a safety profile that is similar to that of placebo and similar or superior to those of other antihypertensive drugs. As part of the aliskiren ASPIRE HIGHER clinical trials program, studies are ongoing in patients with known cardiovascular or renal risk factors and results of these trials will provide additional data on the overall tolerability profile of aliskiren. 
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